Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 106

1.

Impact of variant microscopic interpretation of the uCyt+ immunocytological urine test for the detection of bladder cancer.

Deininger S, Todenhöfer T, Hennenlotter J, Gerber V, Schwarz J, Bedke J, Schwentner C, Stenzl A, Rausch S.

Diagn Cytopathol. 2017 Nov 8. doi: 10.1002/dc.23857. [Epub ahead of print]

PMID:
29115014
2.

Perioperative morbidity, bowel function and oncologic outcome after radical cystectomy and ileal orthotopic neobladder reconstruction: Studer-pouch versus I-pouch.

Mischinger J, Abdelhafez MF, Rausch S, Todenhöfer T, Neumann E, Aufderklamm S, Stenzl A, Gakis G.

Eur J Surg Oncol. 2017 Oct 20. pii: S0748-7983(17)30948-4. doi: 10.1016/j.ejso.2017.10.208. [Epub ahead of print]

PMID:
29108960
3.

A subpopulation of stromal cells controls cancer cell homing to the bone marrow.

Rossnagl S, Ghura H, Groth C, Altrock E, Jakob F, Schott S, Wimberger P, Link T, Kuhlmann JD, Stenzl A, Hennenlotter J, Todenhöfer T, Rojewski M, Bieback K, Nakchbandi IA.

Cancer Res. 2017 Oct 24. pii: canres.3507.2016. doi: 10.1158/0008-5472.CAN-16-3507. [Epub ahead of print]

PMID:
29066511
4.

[TKI 2.0 - changes in the medical treatment of renal cell carcinoma].

Stühler V, Kruck S, Hegemann M, Notohamiprodjo M, Todenhöfer T, Kröger N, Stenzl A, Bedke J.

Urologe A. 2017 Sep 6. doi: 10.1007/s00120-017-0496-z. [Epub ahead of print] Review. German.

PMID:
28879504
5.

Circulating tumor cells and their role in prostate cancer.

Maas M, Hegemann M, Rausch S, Bedke J, Stenzl A, Todenhöfer T.

Asian J Androl. 2017 Aug 22. doi: 10.4103/aja.aja_29_17. [Epub ahead of print] Review.

6.

Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.

Vandekerkhove G, Todenhöfer T, Annala M, Struss WJ, Wong A, Beja K, Ritch E, Brahmbhatt S, Volik SV, Hennenlotter J, Nykter M, Chi KN, North S, Stenzl A, Collins CC, Eigl BJ, Black PC, Wyatt AW.

Clin Cancer Res. 2017 Nov 1;23(21):6487-6497. doi: 10.1158/1078-0432.CCR-17-1140. Epub 2017 Jul 31.

PMID:
28760909
7.

Effect of radical prostatectomy on levels of cancer related epitopes in circulating macrophages of patients with clinically localized prostate cancer.

Todenhöfer T, Hennenlotter J, Keller G, Neumann T, Stenzl A, Bedke J.

Prostate. 2017 Sep;77(12):1251-1258. doi: 10.1002/pros.23384. Epub 2017 Jul 20.

PMID:
28726251
8.

Expression of Epithelial Mesenchymal Transition and Cancer Stem Cell Markers in Circulating Tumor Cells.

Werner S, Stenzl A, Pantel K, Todenhöfer T.

Adv Exp Med Biol. 2017;994:205-228. doi: 10.1007/978-3-319-55947-6_11. Review.

PMID:
28560676
9.

Chronic Periodontitis Does Not Impact Serum Levels of Prostate-specific Antigen.

Kruck S, Hennenlotter J, Amend B, Geiger M, Filipova E, Neumann T, Stühler V, Schubert T, Todenhöfer T, Rausch S, Huettig F, Stenzl A, Bedke J.

Anticancer Res. 2017 Jun;37(6):3163-3167.

PMID:
28551659
10.

An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.

Seiler R, Oo HZ, Tortora D, Clausen TM, Wang CK, Kumar G, Pereira MA, Ørum-Madsen MS, Agerbæk MØ, Gustavsson T, Nordmaj MA, Rich JR, Lallous N, Fazli L, Lee SS, Douglas J, Todenhöfer T, Esfandnia S, Battsogt D, Babcook JS, Al-Nakouzi N, Crabb SJ, Moskalev I, Kiss B, Davicioni E, Thalmann GN, Rennie PS, Black PC, Salanti A, Daugaard M.

Eur Urol. 2017 Jul;72(1):142-150. doi: 10.1016/j.eururo.2017.03.021. Epub 2017 Apr 10.

PMID:
28408175
11.

Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience.

Hegemann M, Bedke J, Stenzl A, Todenhöfer T.

Ther Adv Urol. 2017 Feb 6;9(3-4):81-88. doi: 10.1177/1756287216686018. eCollection 2017 Mar-Apr. Review.

12.

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.

Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjödahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhöfer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall'Era M, van der Heijden MS, Black PC.

Eur Urol. 2017 Oct;72(4):544-554. doi: 10.1016/j.eururo.2017.03.030. Epub 2017 Apr 5.

PMID:
28390739
13.

Prediction of Postoperative Risks in Laparoscopic Partial Nephrectomy Using RENAL, Mayo Adhesive Probability and Renal Pelvic Score.

Bier S, Aufderklamm S, Todenhöfer T, Kruck S, Schuster K, Rausch S, Othman A, Notohamiprodjo M, Nikolaou K, Schwentner C, Stenzl A, Bier G, Bedke J.

Anticancer Res. 2017 Mar;37(3):1369-1373.

PMID:
28314305
14.

Is The Cancer Genome Atlas (TCGA) bladder cancer cohort representative of invasive bladder cancer?

Seiler R, Black PC, Thalmann G, Stenzl A, Todenhöfer T.

Urol Oncol. 2017 Jul;35(7):458.e1-458.e7. doi: 10.1016/j.urolonc.2017.01.024. Epub 2017 Mar 11.

PMID:
28291637
15.

The Value and Evaluability of the PCA3 Urine Assay in Prostate Carcinoma is Independent of the Tumor Localization.

Neumann E, Hennenlotter J, Todenhöfer T, Scharpf M, Neumann T, Schilling D, Stenzl A, Bedke J.

Adv Ther. 2017 Apr;34(4):966-974. doi: 10.1007/s12325-017-0510-2. Epub 2017 Mar 13.

PMID:
28290096
16.

Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?

Anselmo Da Costa I, Rausch S, Kruck S, Todenhöfer T, Stenzl A, Bedke J.

Expert Rev Anticancer Ther. 2017 Apr;17(4):357-368. doi: 10.1080/14737140.2017.1292138. Epub 2017 Feb 20. Review.

PMID:
28162024
17.

Comparison of different concepts for interpretation of chromosomal aberrations in urothelial cells detected by fluorescence in situ hybridization.

Mischinger J, Guttenberg LP, Hennenlotter J, Gakis G, Aufderklamm S, Rausch S, Neumann E, Bedke J, Kruck S, Schwentner C, Stenzl A, Todenhöfer T.

J Cancer Res Clin Oncol. 2017 Apr;143(4):677-685. doi: 10.1007/s00432-016-2310-5. Epub 2016 Dec 2.

PMID:
27913867
18.

Editorial Comment.

Todenhöfer T, Black PC.

J Urol. 2017 Jan;197(1):215. doi: 10.1016/j.juro.2016.08.125. Epub 2016 Oct 13. No abstract available.

PMID:
27746139
19.

Microfluidic enrichment of circulating tumor cells in patients with clinically localized prostate cancer.

Todenhöfer T, Park ES, Duffy S, Deng X, Jin C, Abdi H, Ma H, Black PC.

Urol Oncol. 2016 Nov;34(11):483.e9-483.e16. doi: 10.1016/j.urolonc.2016.06.004. Epub 2016 Sep 19.

PMID:
27658563
20.

Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines.

Schmitz-Dräger BJ, Kuckuck EC, Zuiverloon TC, Zwarthoff EC, Saltzman A, Srivastava A, Hudson MA, Seiler R, Todenhöfer T, Vlahou A, Grossman HB, Schoenberg MP, Sanchez-Carbayo M, Brünn LA, van Rhijn BW, Goebell PJ, Kamat AM, Roupret M, Shariat SF, Kiemeney LA.

Urol Oncol. 2016 Oct;34(10):437-51. doi: 10.1016/j.urolonc.2016.05.030. Epub 2016 Sep 15. Review.

PMID:
27641313

Supplemental Content

Loading ...
Support Center